Duloxetine for Chronic Depression: a Double-blind Study

Status Completed

Clinical Trial Summary

The investigators are studying a new antidepressant medicine, duloxetine, for the treatment of people with chronic depression. Duloxetine (trade name Cymbalta) was recently approved by the FDA for the treatment of major depression. The investigators are testing whether this medicine is also effective for adults with chronic depression (dysthymic disorder or dysthymia).

Chronic depression, lasting two or more years, often causes significant suffering and impairment. The investigators study involves a 6 to 10 week double-blind Initial Phase during which half of the participants will take the new medication and half will take a placebo (an inactive look-alike pill). After the Initial Phase, a 12-week Continuation Phase will begin, during which all subjects can be treated with an FDA-approved antidepressant medication.

Eligible subjects may also receive MRI scans, to help the investigators understand how antidepressants work in treating depression.

Clinical Trial Description

This is a 22-week study of the tolerability, dosing, and efficacy of duloxetine in chronically depressed outpatients. Participants can have Dysthymic Disorder (Dysthymia), or Depression, Not Otherwise Specified (Depression NOS).

The first 10 weeks (Acute Phase) are double blind, placebo-controlled, and the second 12 weeks (Continuation Phase) is open-label and all subjects will receive active medication.

Tests of cytokine functioning will be performed and analyzed for treatment and placebo effects.

In addition, a subset of patients will be enrolled into an Magnetic Resonance Imaging (MRI) sub-study, in which a variety of brain imaging techniques (including anatomical MRI, functional MRI (fMRI), MR Spectroscopy, and Diffusion Tensor Imaging) will be performed at baseline and week 10. Duloxetine responders will have a third MRI performed at week 22. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00360724
Study type	Interventional
Source	New York State Psychiatric Institute
Contact
Status	Completed
Phase	Phase 4
Start date	August 2006
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01583400` - Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial	N/A
Recruiting	`NCT00260390` - Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial	Phase 4
Completed	`NCT00518986` - Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression	Phase 4
Completed	`NCT04437485` - eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk	Phase 2
Completed	`NCT01892124` - Motivational Interviewing and Cognitive Behavioral Therapy-based Intervention for Cardiovascular Disease Prevention Amongst American Indians With Diabetic and Depressive Symptoms	N/A
Active, not recruiting	`NCT01473615` - Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression	N/A
Completed	`NCT01542957` - Cognitive Therapy for Unipolar Depression: Efficacy of a Dilemma-Focused Intervention	N/A
Completed	`NCT00619411` - Interpersonal Psychotherapy for Depressed Adolescents and Parents	Phase 1
Completed	`NCT00225251` - Wellbutrin XL for Dysthymic Disorder	Phase 4
Recruiting	`NCT03507114` - Rumination Focus Cognitive Behavior Therapy	N/A
Recruiting	`NCT03917550` - RECOVERY: A Transdiagnostic Intervention for Anxiety and Depression	N/A
Completed	`NCT00688818` - Quetiapine in Co-Morbid Depressive and Anxiety Disorders	N/A
Completed	`NCT00220701` - Escitalopram in the Treatment of Dysthymic Disorder, Double Blind	Phase 4
Completed	`NCT00096642` - Cognitive Behavioral Therapy for Early-Onset Depression	N/A
Completed	`NCT02458690` - eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients	Phase 2
Completed	`NCT00883519` - The Efficacy of Parent Involvement in the Treatment of Adolescent Depression	Phase 1/Phase 2
Completed	`NCT01852383` - Duloxetine Treatment in Elderly With Dysthymia	Phase 4
Completed	`NCT01561105` - Improving Depression Care for Elders: Coordinating Center	N/A
Not yet recruiting	`NCT05118594` - Testing a Precision Psychotherapy System for Low-income Patients	N/A
Completed	`NCT01537068` - Desvenlafaxine vs. Placebo Treatment of Chronic Depression	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.